Home >> Signaling Pathways >> Tyrosine Kinase >> Ephrin Receptor

Ephrin Receptor

Ephrin receptors (Ephs) are a group of receptors that are activated in response to binding ephrin. Ephs form the largest known subfamily of receptor tyrosine kinases (RTKs). Both Ephs and their corresponding ephrin ligands are membrane-bound proteins that require direct cell-cell interactions for Eph receptor activation. Eph/ephrin signaling has been implicated in the regulation of a host of processes critical to embryonic development including axon guidance, formation of tissue boundaries, cell migration, and segmentation. Additionally, Eph/epherin signaling has recently been identified to play a critical role in the maintenance of several processes during adulthood including long-term potentiation, angiogenesis, and stem cell differentiation and cancer. The ability of Ephs and ephrins to mediate a variety of cell-cell interactions places the Eph/ephrin system in an ideal position to regulate a variety of different biological processes during embryonic development.

Targets for  Ephrin Receptor

Products for  Ephrin Receptor

  1. Cat.No. Product Name Information
  2. GC35053 123C4 123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4, with a Ki value of 0.65 μM. 123C4  Chemical Structure
  3. GC11134 ALW-II-41-27

    Eph receptor tyrosine kinase inhibitor;

    ALW-II-41-27 is an Eph family tyrosine kinase inhibitor with an IC50 of 11 nM to inhibit Eph2. ALW-II-41-27  Chemical Structure
  4. GC68647 ALW-II-49-7

    ALW-II-49-7 is a selective inhibitor of EphB2 with an intracellular EC50 of 40 nM.

    ALW-II-49-7  Chemical Structure
  5. GC25367 Ehp-inhibitor-1

    Ehp inhibitor 2

    Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors. Ehp-inhibitor-1  Chemical Structure
  6. GC69258 Ifabotuzumab

    KB004

    Ifabotuzumab (KB004) is an IgG1κ antibody that targets EphA3 (KD=610 pM). Ifabotuzumab can induce apoptosis in tumor cells and activate antibody-dependent cell-mediated cytotoxicity (ADCC), which destroys the tumor vascular system. Ifabotuzumab can reduce CCR10+ cells in idiopathic pulmonary fibrosis (IPF) patients, improving lung fibrosis.

    Ifabotuzumab  Chemical Structure
  7. GC18168 JI-101

    CGI1842

    An orally active inhibitor

    JI-101  Chemical Structure
  8. GC50137 KYL KYL, an antagonistic peptide, selectively targets EphA4 receptor. KYL  Chemical Structure
  9. GC14332 NVP-BHG712 EphB4 inhibitor,potent and selective NVP-BHG712  Chemical Structure
  10. GC36782 NVP-BHG712 isomer NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4. NVP-BHG712 isomer  Chemical Structure
  11. GC74367 Targefrin Targefrin is a potent EphA2-targeting agent, acts as an antagonist. Targefrin  Chemical Structure
  12. GC31752 Tesevatinib (XL-647)

    EXEL-7647, Tesevatinib

    Tesevatinib (XL-647) (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM. Tesevatinib (XL-647)  Chemical Structure
  13. GC64856 UniPR129 UniPR129 is a potent Eph/ephrin antagonist. UniPR129 has the potential for the research of cancer disease. UniPR129  Chemical Structure
  14. GC70097 Urolithin D

    Urolithin D is a competitive and reversible antagonist of the EphA receptor. Urolithin D exhibits intra-class selectivity.

    Urolithin D  Chemical Structure

13 Item(s)

per page

Set Descending Direction